Positive News SentimentPositive News Inventiva Stock Price, News & Analysis (NASDAQ:IVA) $4.46 +0.14 (+3.24%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$4.33▼$4.4950-Day Range$3.62▼$4.4652-Week Range$2.22▼$6.82Volume9,066 shsAverage Volume51,238 shsMarket Capitalization$230.82 millionP/E RatioN/ADividend YieldN/APrice Target$16.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Inventiva MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside267.7% Upside$16.40 Price TargetShort InterestHealthy0.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.21) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector365th out of 952 stocksPharmaceutical Preparations Industry162nd out of 434 stocks 3.5 Analyst's Opinion Consensus RatingInventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.40, Inventiva has a forecasted upside of 267.7% from its current price of $4.46.Amount of Analyst CoverageInventiva has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.17% of the outstanding shares of Inventiva have been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Inventiva has recently decreased by 1.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVA. Previous Next 3.8 News and Social Media Coverage News SentimentInventiva has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.Search Interest1 people have searched for IVA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Inventiva to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.46% of the stock of Inventiva is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inventiva are expected to grow in the coming year, from ($2.21) to ($2.07) per share.Price to Book Value per Share RatioInventiva has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inventiva Stock (NASDAQ:IVA)Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Read More IVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVA Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comInventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASHNovember 24, 2023 | americanbankingnews.comBrokerages Set Inventiva S.A. (NASDAQ:IVA) PT at $16.40December 4, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.November 22, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Morphosys Ag (MOR), Abbott Labs (ABT)November 21, 2023 | finanznachrichten.deINVENTIVA: Inventiva reports 2023 Third Quarter Financial InformationNovember 21, 2023 | msn.comInventiva reports 9M resultsNovember 21, 2023 | finance.yahoo.comInventiva reports 2023 Third Quarter Financial Information¹November 12, 2023 | lse.co.ukInventiva Share Price (IVA.PA)December 4, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.November 9, 2023 | markets.businessinsider.comHold Rating on Madrigal Pharmaceuticals Amid Potential and Uncertainties: FDA Review, Commercial Launch, and Mixed Data ImpactNovember 6, 2023 | finance.yahoo.comInventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023October 27, 2023 | finance.yahoo.comNon-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51% of market growth- TechnavioOctober 2, 2023 | markets.businessinsider.comPositive Prospects for Inventiva: Pivotal NATiV3 Trial Progress, Anticipated LEGEND Study Results, and Expansion into Asian MarketsSeptember 28, 2023 | finanznachrichten.deINVENTIVA: Inventiva reports its 2023 first-half financial results and provides a corporate updateSeptember 28, 2023 | finance.yahoo.comInventiva reports its 2023 first-half financial results and provides a corporate updateSeptember 21, 2023 | markets.businessinsider.comInvestors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties EaseSeptember 21, 2023 | markets.businessinsider.comPre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…September 20, 2023 | marketwatch.comInventiva ADRs Rise 9% Following Licensing DealSeptember 20, 2023 | finance.yahoo.comInventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South KoreaSeptember 20, 2023 | finance.yahoo.comInventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South KoreaSeptember 12, 2023 | msn.comIndustry slow to embrace new fatty liver disease nomenclatureAugust 31, 2023 | msn.comurban-gro announces sale of investment for proceeds of $2.3 millionAugust 31, 2023 | msn.comInventiva announced €35.7M funding, eyes future raise to meet obligationsAugust 31, 2023 | finance.yahoo.comInventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificatesAugust 14, 2023 | msn.comDrugmakers still chasing potentially lucrative NASH market, despite setbacksJuly 28, 2023 | finanznachrichten.deINVENTIVA: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business updateJuly 28, 2023 | finance.yahoo.comCorrection: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business updateSee More Headlines Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IVA CUSIPN/A CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees117Year Founded2011Price Target and Rating Average Stock Price Target$16.40 High Stock Price Target$35.00 Low Stock Price Target$11.00 Potential Upside/Downside+267.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.37 Sales & Book Value Annual Sales$12.83 million Price / Sales17.99 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book3.91Miscellaneous Outstanding Shares51,750,000Free Float35,192,000Market Cap$230.81 million OptionableNot Optionable Beta0.92 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Frederic Cren (Age 57)Co-Founder, CEO & Chairman Comp: $550.18kDr. Pierre Broqua Ph.D. (Age 61)Co-Founder, Chief Scientific Officer, Deputy CEO & Director Comp: $412.67kMr. Jean Volatier (Age 58)Chief Financial Officer Alice Roudot-Ketelers Pharm.D.Chief Operating OfficerMr. Eric Duranson L.L.M. (Age 49)General Counsel Ms. Nathalie Harroy (Age 56)Head of Human Resources Dr. Irena KonstantinovaHead of Biology & PharmacologyDr. Michael Cooreman (Age 65)Chief Medical Officer Mr. Jean-Paul Dutertre M.D.Head of PharmacovigilanceMore ExecutivesKey CompetitorsRepare TherapeuticsNASDAQ:RPTXEnanta PharmaceuticalsNASDAQ:ENTAAEON BiopharmaNASDAQ:AEONVanda PharmaceuticalsNASDAQ:VNDAImmuneeringNASDAQ:IMRXView All CompetitorsInstitutional OwnershipCommonwealth Equity Services LLCBought 4,155 shares on 10/23/2023Ownership: 0.047%View All Institutional Transactions IVA Stock Analysis - Frequently Asked Questions Should I buy or sell Inventiva stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVA shares. View IVA analyst ratings or view top-rated stocks. What is Inventiva's stock price target for 2024? 7 brokers have issued 1-year price targets for Inventiva's stock. Their IVA share price targets range from $11.00 to $35.00. On average, they expect the company's stock price to reach $16.40 in the next year. This suggests a possible upside of 267.7% from the stock's current price. View analysts price targets for IVA or view top-rated stocks among Wall Street analysts. How have IVA shares performed in 2023? Inventiva's stock was trading at $4.46 at the start of the year. Since then, IVA stock has increased by 0.0% and is now trading at $4.46. View the best growth stocks for 2023 here. When did Inventiva IPO? (IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. Who are Inventiva's major shareholders? Inventiva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Commonwealth Equity Services LLC (0.05%). How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IVA) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.